Organization
Division of Hematology & Oncology
13 abstracts
Abstract
Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.Org: Massachusetts General Hospital, Harvard University, Division of Hematology & Oncology, Harvard Medical School, UMass Memorial Cancer Center,
Abstract
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program study.Org: VA Puget Sound Health Care System, Veterans Healthcare Administration, Corporal Michael Crescenz VA Medical Center, Genetic Support Foundation, VA Million Veteran Program,
Abstract
Hematologic toxicity in 177lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV).Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.Org: Fred Hutchinson Cancer Center, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington/Fred Hutch Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.Org: Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Research Center,
Abstract
Implementing a research methods curriculum for first year hematology oncology fellows.Org: Division of Hematology & Oncology, Heersink School of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Massachusetts General Cancer Center, Boston, MA,
Abstract
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Examining laboratory-based VISION eligibility and 177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).Org: Medical College of Wisconsin, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Wisconsin Madison School of Medicine and Public Health, Division of Hematology & Oncology,
Abstract
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
“It’s been a long journey:” A qualitative study of patient and caregiver experiences during multimodality treatment for locally advanced rectal cancer.Org: Massachusetts General Hospital, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Harvard Medical School, University of Oklahoma Stephenson Cancer Center,